Ella Fitszimmons
Sep 10, 2008

Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

Xian Janssen shifts two brands to Bates141
DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Source:
Campaign China

Related Articles

Just Published

48 minutes ago

TikTok encourages brands to ‘take more exciting ...

Platform identified trends including ‘tapping into girlhood’ and working with more content creators.

18 hours ago

Spikes Asia 2025: Rika Komakine and Tetsuya Honda ...

A Japanese PR agency and their client cooked up a Spikes Asia Award-winning campaign by tackling a common cooking complaint—sticky gyoza. This is how they did it.

19 hours ago

Meta could soon be the largest misinformation ...

The tech company’s recent changes could result in a surge in unmoderated and unfortunate content, underscoring the need for advertisers to again be mindful about where they spend their dollars, writes Sarah Thompson.

19 hours ago

WPP mandates four days per week in office

The change to the global guidelines will apply across WPP's operations.